Bibliografia UJ CM

1/6
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Prognostic Risk Factors in the HR-NBL-1/SIOPEN Study in Patients Receiving Dinutuximab Beta (DB) Based Immunotherapy.
Pediatric Blood & Cancer
2020 : Vol. 67, suppl. 4, s. S265, abstr. 0586
Abstracts from the 52th Congress of the International Society of Paediatric Oncology (SIOP) Virtual Congress, October 14-17, 2020.
p-ISSN: 1545-5009
SZZ
SIF
Adres url:
2/6
L. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, H. Loibner, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients.
Pediatric Blood & Cancer
2019 : Vol. 66, suppl. 4, s. S31-S32, abstr. FP049 SIOP19-0117
51st Congress of the International Society of Paediatric Oncology (SIOP), Lyon, France,October 23-26, 2019.
p-ISSN: 1545-5009
SZZ
SIF
3/6
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, V. Castel, M. Elliott, S. Ash, G. Chan, G. Laureys, M. Beck-Popovic, K. Vettenranta, W[alentyna] Balwierz, H. Schroeder, C. Owens, M. Cesen, V. Papadakis, T. Trahair, R. Luksch, G. Schleiermacher, P. Ambros, A. Garaventa.
The Randomised Induction for High-Risk Neuroblastoma Comparing COJEC and N5-MSKCC Regimens. Early Results from the HR-NBL1.5/SIOPEN Trial.
Pediatric Blood & Cancer
2018 : Vol. 65, suppl. 2, s. S11, abstr. O-013.
p-ISSN: 1545-5009
SZZ
SIF
4/6
R. Ladenstein, U. Poetschger, P. Brock, R. Luksch, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W[alentyna] Balwierz, P. Kogner, P. Ambros, K. Holmes, M. Gaze, G. Schreier, A. Garaventa, G. Vassal, J. Michon, A. Pearson, D. Valteau-Couanet.
Long-Term Results for Children with High-Risk Neuroblastoma Treated on the Randomized High-Dose Therapy Trial of Busulphan-Melphalan Versus Carboplatin-Etoposide-Melphalan: A Siopen Study.
Pediatric Blood & Cancer
2016 : Vol. 63, Suppl. 3, s. S32, abstr. O-106.
48th Congress of the International Society of Paediatric Oncology (SIOP) Dublin, Ireland, October 19-22, 2016.
p-ISSN: 1545-5009
SZZ
SIF
5/6
R. Ladenstein, U. Poetschger, M. Elliot, R. Luksch, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W[alentyna] Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz de Lacerda, M. Beck-Popovic, P. Bician, M. Garami, T. Trahair, P. Ambros, K. Holmes, G. Schreier, M. Gaze, A. Pearson, D. Valteau-Couanet, SIOP Europe Neuroblastoma Grp.
Risk factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN TRIAL.
Bone Marrow Transplantation
2016 : Vol. 51, suppl. 1, s. S46, abstr. O072.
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, Spain, APR 03-06, 2016.
p-ISSN: 0268-3369
SZZ
SIF
6/6
R. Ladenstein, U. Poetschger, R. Luksch, M. Elliot, V. Castel, I. Yaniv, G. Laureys, W[alentyna] Balwierz, H.N. Lode, D. Valteau-Couanet.
Myeloablative therapy (MAT) and immunotherapy (IT) with ch14.18/cho for high risk neuroblastoma: update and news of randomised results from the HR-NBL1/SIOPEN trial.
Pediatric Blood & Cancer
2014 : Vol. 61, Suppl. 2, s. S122-S123, abstr. O-063.
p-ISSN: 1545-5009
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ